S&P 500   5,057.00 (+1.51%)
DOW   38,866.42 (+0.66%)
QQQ   435.71 (+2.37%)
AAPL   183.15 (+0.46%)
MSFT   411.53 (+2.32%)
META   486.42 (+3.93%)
GOOGL   144.03 (+1.04%)
AMZN   172.77 (+2.48%)
TSLA   192.24 (-1.30%)
NVDA   779.33 (+15.50%)
NIO   5.75 (-3.69%)
AMD   180.72 (+10.00%)
BABA   75.65 (+0.09%)
T   16.61 (-2.29%)
F   12.18 (+0.33%)
MU   85.52 (+4.95%)
CGC   3.43 (-0.29%)
GE   151.10 (+1.36%)
DIS   108.05 (+0.35%)
AMC   4.48 (-1.97%)
PFE   27.27 (-1.45%)
PYPL   57.70 (+0.38%)
XOM   104.69 (-0.15%)
S&P 500   5,057.00 (+1.51%)
DOW   38,866.42 (+0.66%)
QQQ   435.71 (+2.37%)
AAPL   183.15 (+0.46%)
MSFT   411.53 (+2.32%)
META   486.42 (+3.93%)
GOOGL   144.03 (+1.04%)
AMZN   172.77 (+2.48%)
TSLA   192.24 (-1.30%)
NVDA   779.33 (+15.50%)
NIO   5.75 (-3.69%)
AMD   180.72 (+10.00%)
BABA   75.65 (+0.09%)
T   16.61 (-2.29%)
F   12.18 (+0.33%)
MU   85.52 (+4.95%)
CGC   3.43 (-0.29%)
GE   151.10 (+1.36%)
DIS   108.05 (+0.35%)
AMC   4.48 (-1.97%)
PFE   27.27 (-1.45%)
PYPL   57.70 (+0.38%)
XOM   104.69 (-0.15%)
S&P 500   5,057.00 (+1.51%)
DOW   38,866.42 (+0.66%)
QQQ   435.71 (+2.37%)
AAPL   183.15 (+0.46%)
MSFT   411.53 (+2.32%)
META   486.42 (+3.93%)
GOOGL   144.03 (+1.04%)
AMZN   172.77 (+2.48%)
TSLA   192.24 (-1.30%)
NVDA   779.33 (+15.50%)
NIO   5.75 (-3.69%)
AMD   180.72 (+10.00%)
BABA   75.65 (+0.09%)
T   16.61 (-2.29%)
F   12.18 (+0.33%)
MU   85.52 (+4.95%)
CGC   3.43 (-0.29%)
GE   151.10 (+1.36%)
DIS   108.05 (+0.35%)
AMC   4.48 (-1.97%)
PFE   27.27 (-1.45%)
PYPL   57.70 (+0.38%)
XOM   104.69 (-0.15%)
S&P 500   5,057.00 (+1.51%)
DOW   38,866.42 (+0.66%)
QQQ   435.71 (+2.37%)
AAPL   183.15 (+0.46%)
MSFT   411.53 (+2.32%)
META   486.42 (+3.93%)
GOOGL   144.03 (+1.04%)
AMZN   172.77 (+2.48%)
TSLA   192.24 (-1.30%)
NVDA   779.33 (+15.50%)
NIO   5.75 (-3.69%)
AMD   180.72 (+10.00%)
BABA   75.65 (+0.09%)
T   16.61 (-2.29%)
F   12.18 (+0.33%)
MU   85.52 (+4.95%)
CGC   3.43 (-0.29%)
GE   151.10 (+1.36%)
DIS   108.05 (+0.35%)
AMC   4.48 (-1.97%)
PFE   27.27 (-1.45%)
PYPL   57.70 (+0.38%)
XOM   104.69 (-0.15%)

Repligen (RGEN) Competitors

$198.76
+4.66 (+2.40%)
(As of 10:40 AM ET)

RGEN vs. NBIX, EXEL, HALO, DNLI, ADPT, BIIB, TECH, QGEN, PCVX, and CRSP

Should you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Neurocrine Biosciences (NBIX), Exelixis (EXEL), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), Biogen (BIIB), Bio-Techne (TECH), Qiagen (QGEN), Vaxcyte (PCVX), and CRISPR Therapeutics (CRSP). These companies are all part of the "biological products, except diagnostic" industry.

Repligen vs.

Neurocrine Biosciences (NASDAQ:NBIX) and Repligen (NASDAQ:RGEN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.

Repligen has a net margin of 17.29% compared to Repligen's net margin of 13.23%. Repligen's return on equity of 12.85% beat Neurocrine Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Neurocrine Biosciences13.23% 12.85% 9.02%
Repligen 17.29%6.08%4.69%

93.5% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 1.1% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Repligen had 5 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 21 mentions for Repligen and 16 mentions for Neurocrine Biosciences. Repligen's average media sentiment score of 0.50 beat Neurocrine Biosciences' score of 0.47 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Neurocrine Biosciences
5 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Repligen
4 Very Positive mention(s)
2 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Neurocrine Biosciences received 568 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 77.55% of users gave Neurocrine Biosciences an outperform vote while only 67.97% of users gave Repligen an outperform vote.

CompanyUnderperformOutperform
Neurocrine BiosciencesOutperform Votes
967
77.55%
Underperform Votes
280
22.45%
RepligenOutperform Votes
399
67.97%
Underperform Votes
188
32.03%

Neurocrine Biosciences currently has a consensus target price of $136.69, suggesting a potential upside of 4.62%. Repligen has a consensus target price of $192.50, suggesting a potential downside of 0.82%. Given Repligen's higher probable upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Repligen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neurocrine Biosciences
0 Sell rating(s)
6 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.75
Repligen
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Neurocrine Biosciences has higher revenue and earnings than Repligen. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$1.89B6.89$249.70M$2.4253.99
Repligen$801.54M13.52$185.96M$2.0395.62

Neurocrine Biosciences has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Summary

Neurocrine Biosciences beats Repligen on 11 of the 18 factors compared between the two stocks.


Get Repligen News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGEN vs. The Competition

MetricRepligenBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$10.84B$2.68B$4.98B$7.33B
Dividend YieldN/A2.40%2.92%3.85%
P/E Ratio95.627.84119.9318.18
Price / Sales13.52279.912,971.7757.57
Price / Cash47.9422.1691.0754.06
Price / Book5.643.844.304.56
Net Income$185.96M$60.70M$112.67M$207.35M
7 Day Performance-5.79%-0.35%0.68%-0.95%
1 Month Performance5.36%9.15%5.95%3.18%
1 Year Performance14.19%4.37%6.54%3.35%

Repligen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBIX
Neurocrine Biosciences
4.8719 of 5 stars
$133.84
+2.6%
$136.69
+2.1%
+28.0%$13.15B$1.89B55.311,200High Trading Volume
EXEL
Exelixis
4.9992 of 5 stars
$20.23
-0.8%
$25.94
+28.2%
+18.7%$6.13B$1.83B31.611,310
HALO
Halozyme Therapeutics
4.9737 of 5 stars
$34.64
-2.9%
$51.45
+48.5%
-22.8%$4.58B$660.12M18.43393Analyst Report
News Coverage
Gap Up
DNLI
Denali Therapeutics
3.9706 of 5 stars
$17.06
-8.0%
$48.20
+182.5%
-42.5%$2.37B$108.46M-17.59447Upcoming Earnings
Analyst Report
ADPT
Adaptive Biotechnologies
3.645 of 5 stars
$3.62
-7.7%
$7.67
+111.8%
-56.6%$524.07M$185.31M-2.66790Analyst Revision
BIIB
Biogen
4.992 of 5 stars
$226.65
-7.4%
$317.52
+40.1%
-18.7%$32.84B$10.17B22.538,725Analyst Report
Insider Buying
High Trading Volume
TECH
Bio-Techne
4.9841 of 5 stars
$67.52
-3.5%
$84.11
+24.6%
-2.6%$10.61B$1.14B48.933,050Positive News
QGEN
Qiagen
4.7717 of 5 stars
$42.86
-2.2%
$51.79
+20.8%
-12.0%$9.48B$1.97B28.336,178Analyst Revision
PCVX
Vaxcyte
0.0979 of 5 stars
$73.91
-3.3%
$68.40
-7.5%
+64.0%$7.03BN/A-22.13158Upcoming Earnings
CRSP
CRISPR Therapeutics
1.171 of 5 stars
$72.78
-4.8%
$68.39
-6.0%
+76.7%$5.78B$1.20M-16.28473Earnings Report
Analyst Report
Insider Selling
Analyst Revision
News Coverage
Gap Down

Related Companies and Tools

This page (NASDAQ:RGEN) was last updated on 2/22/2024 by MarketBeat.com Staff